Uipath Inc (PATH) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Uipath Inc stock $14.58, price $12.98, upside +12.3%, quality 81 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $9.38 – $64.97 · fair‑value band $9.53 – $22.68 · the $12.98 price screens below the $14.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Uipath in your weekly email
Every Wednesday you see whether Uipath is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
UiPath, Inc. provides an automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally.
Show moreShow less
It offers the UiPath platform, an integrated enterprise software platform that enables AI agents, robots, people, and models to work together in coordinated workflows.
The company's UiPath platform includes the UiPath Maestro process orchestration and process intelligence; UiPath agent builder; RPA and API automation; UiPath intelligent xtraction and processing; UiPath test cloud for testing and quality assurance; UiPath packaged and prebuilt agentic solutions; and centralized governance capabilities that apply across automations, AI agents, and manual tasks.
It serves the financial services, healthcare, manufacturing, retail, and public sectors. The company was founded in 2005 and is headquartered in New York, New York.
Stock analysis
Uipath Inc (PATH) currently trades at $12.98, while our model-based Fair Value estimate is $14.58, implying the stock looks roughly 11% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $21.63 per share, and 12 of the 24 models we run sit above the $12.98 price.
Bear case: the Asset-Based group reads lowest at $2.51, and 12 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: $9.53 (bear) to $22.68 (bull), the price of $12.98 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Technology sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Uipath Inc reported revenue of $1.6B in FY2026 versus $892M in FY2022, a compound +15.9%/yr. Reported net income was $282M in FY2026.
Key figures
Market cap $7.1B Mid · P/E ratio 20.5 · P/S ratio 4.11 · EPS (TTM) $0.6700 · Net margin 21.0% · Return on equity 20.0% · Return on assets (EBIT) −8.3% (5-year average) · Operating margin 8.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Technology peers we cover trades at −14% fair-value upside, at 12%, PATH screens cheaper than that median.
Fair Value models
Bear$9.53Fair Value $14.58Bull$22.68
Price $12.98 · Upside +12.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 9 months old). Earnings retained since then ($0.5195 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 5 officers or directors sold shares worth $62.0M and none bought.
SaleRaghavendra MalpaniCPO & CTO4× since Sep 16, 2026: 198,022 shares, avg. $13.83$2.7MOct 22, 202610b5-1 plan
SaleDaniel DinesCEO and Chairman, Director, 10% owner26× since Dec 5, 2025: 5,297,347 shares, avg. $14.92$79.0MOct 16, 202610b5-1 plan
SaleBrad BrubakerChief Legal & Admin Officer2× since Dec 5, 2025: 54,984 shares, avg. $16.10$885,164Oct 12, 202610b5-1 plan
SaleAshim GuptaCOO3× since Jan 5, 2026: 250,859 shares, avg. $14.28$3.6MOct 2, 202610b5-1 plan
SaleHitesh RamaniChief Accounting Officer50,000 shares at $16.63$831,250Aug 14, 202610b5-1 plan
Plus 21 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.6%
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−18.2% (2021) → 3.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +3.0% a year for the price and +5.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Moderate margins and software traits support a reasonable business position, yet the highly competitive sector restricts any durable moat signals.
Main risk: Generative AI tools might automate tasks that UiPath's core RPA products handle today, reducing demand for its traditional bots among enterprise customers.
Bull case: UiPath could integrate generative AI deeply into its agentic automation platform to orchestrate both AI agents and RPA bots, expanding its role in enterprise workflows and retaining customers.
Bear case: If generative AI commoditises RPA and cheaper rivals like Microsoft capture market share while key customers reduce spending, UiPath's revenue and ARR could decline significantly over the coming years.
UiPath contends with intensifying competition in enterprise AI, which analysts cite as raising the risk of downward revisions to growth estimates. Our models continue to see the shares as undervalued. Will its push into agentic automation and ARR expansion strengthen its position against rivals, or will the competitive pressure limit sustained progress?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Infrastructure · 413 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score81 · Top 25%
Fair Value upside+12.3% · Above median
Profitability
Return on equity (12 months)20.0% · Top 25%
Return on assets8.9% · Top 25%
Net margin (12 months)21.0% · Top 25%
Operating margin (12 months)8.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)13.4% · Above median
Valuation Multiplesvs Software - Infrastructure median · lower = cheaper
P/E (12 months)20.5× · Cheaper than median
P/B3.40× · Pricier than median
P/S (12 months)4.11× · Pricier than median
Price / free cash flow (fiscal year)20.1× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Uipath Inc Fair Value". https://www.fairvalue-calculator.com/stock/PATH
Frequently asked questions
Is Uipath Inc (PATH) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $14.58 versus a price of $12.98, about +12% upside (undervalued).
What is the fair value of PATH?
Our model-based fair value for Uipath Inc is $14.58 (as of Nov 9, 2026), built from audited fundamentals. The current price: $12.98.
What is the quality score of PATH?
Uipath Inc has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Uipath Inc (PATH)?
Our model-based price target is the fair value of $14.58 (as of Nov 9, 2026) from 24 valuation models. Cautious scenario $9.53, optimistic scenario $22.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Uipath Inc stock forecast for 2026?
Our models put fair value at $14.58, about +12% upside versus a price of $12.98 (undervalued). Cautious scenario $9.53, optimistic scenario $22.68. The calculation is refreshed regularly with new filings.
What is the revenue of Uipath Inc (PATH)?
Uipath Inc reported trailing-twelve-month revenue of about $1.7B (latest available figure, as of Nov 9, 2026).
What growth is priced into Uipath Inc (PATH)?
For today's price to be fair in a discounted-cash-flow model, Uipath Inc would have to grow free cash flow by +5.5 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.5 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of PATH use?
Our models discount Uipath Inc at 9.8 %: a base by market capitalisation (mid), damped by beta 1.01, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Uipath Inc that is +5.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Uipath Inc (PATH) delivered so far?
Over the past 5 years revenue at Uipath Inc grew +21.5 % a year. The price currently implies free-cash-flow growth of +5.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Uipath Inc (PATH) growing?
The median revenue growth in the sector is +11.4 % a year. That is the yardstick for the growth priced into Uipath Inc (+5.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Uipath Inc (PATH)?
The free-cash-flow yield on the price is 4.98 %: that much free cash flow Uipath Inc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Uipath Inc (PATH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Uipath Inc it is $14.58 per share (as of Nov 9, 2026), against a price of $12.98. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Uipath Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, PATH trades below its calculated fair value: price $12.98, fair value $14.58, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PATH?
No. The price is what the market pays today ($12.98); the fair value is what the company's own numbers justify ($14.58). For Uipath Inc the two are $1.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Uipath Inc worth?
The market values Uipath Inc at about $7.1B (market capitalisation, as of Nov 9, 2026). Per share that is $12.98; our models calculate a fair value of $14.58 per share.
What do the bullish and bearish scenarios say about PATH?
Our models span a range for Uipath Inc: cautious scenario $9.53, base $14.58, optimistic $22.68 per share (as of Nov 9, 2026, price $12.98). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PATH?
Uipath Inc trades at a price-to-earnings ratio of 20.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $14.58 is built from several models across several years. Other multiples: PEG 0.5, P/B 3.4, P/S 4.1, EV/EBITDA 33.6.
What is the PEG ratio of PATH?
The PEG ratio of Uipath Inc is 0.48 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Uipath Inc (PATH)?
Balance-sheet figures for Uipath Inc (as of Nov 9, 2026): return on equity 20.0%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is PATH from its 52-week high?
Uipath Inc trades at $12.98, about 33% below its 52-week high of $19.29 and 38% above the low of $9.38 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $14.58 is for.
Which stocks are comparable to Uipath Inc?
From the same area (Technology) we also value Microsoft Corporation, Oracle Corporation, Palantir Technologies Inc, Palo Alto Networks, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Uipath Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $12.98, calculated fair value $14.58 (+12%), Quality Score 81/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PATH calculated?
We run Uipath Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $14.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Uipath Inc currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Uipath Inc (PATH)?
The closing price on Nov 9, 2026 was $12.98. Our model-based fair value is $14.58, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Uipath Inc right now?
A fairly wide model range ($9.53 to $22.68) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Uipath Inc
How large is the market capitalisation of Uipath Inc (PATH)?
The market capitalisation of Uipath Inc is $7.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Uipath Inc (PATH)?
The price-to-sales ratio of Uipath Inc is 4.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Uipath Inc (PATH)?
Earnings per share at Uipath Inc are $0.6700 (price ÷ EPS = P/E 20.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Uipath Inc (PATH)?
The net margin of Uipath Inc is 21.0% (last twelve months), excl. one-off gain FY2026 12.3%. How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Uipath Inc (PATH)?
The return on equity (ROE) of Uipath Inc is 20.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Uipath Inc (PATH)?
On an EBIT basis the return on assets of Uipath Inc is −8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Uipath Inc (PATH)?
The operating margin of Uipath Inc is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Uipath Inc (PATH)?
Revenue at Uipath Inc is growing +13.4% versus a year earlier (3y avg +15.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Uipath Inc (PATH)?
Earnings per share at Uipath Inc are growing +22.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Uipath Inc (PATH) hold?
Uipath Inc holds more cash than debt, $800M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Uipath Inc in the live analysis
One click puts Uipath Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026